Document 0543
 DOCN  M9440543
 TI    Cytomegalovirus retinitis and AIDS in Edinburgh.
 DT    9404
 AU    Dhillon B; Maclean H; Eddyshaw D; Cheong I; Flegg P; Brettle R; Princess
       Alexandra Eye Pavilion, Edinburgh, UK.
 SO    Int J STD AIDS. 1993 Nov-Dec;4(6):339-41. Unique Identifier : AIDSLINE
       MED/94137869
 AB    The medical records, retinal drawings and fundus photographs of all
       patients with cytomegalovirus retinitis (CMVR) and AIDS in Edinburgh
       between 1986-1992 were reviewed to determine the efficacy of treatment
       in preserving vision. Ophthalmoscopic features of CMVR were observed in
       32 eyes of 24 patients with AIDS, 19 males and 5 females. HIV
       transmission in this group was by homo/bisexual contact (16), injection
       drug use (7) and blood transfusion (1). Unilateral blurring was the
       commonest visual symptom although 9 (38%) patients had no visual
       symptoms. All patients presented with a corrected visual acuity of 6/12
       or better in at least one eye. Following treatment with systemic
       ganciclovir or foscarnet 16 patients (66%) developed toxic side-effects
       of therapy and 13 (54%) experienced a recurrence of CMVR. Four (17%)
       patients developed a retinal detachment in one eye. The mean survival
       was 8.3 months after the diagnosis of CMVR. At final follow-up, between
       2-26 months after the diagnosis of CMVR, 21 (87.5%) patients retained
       useful vision (6/18 or better) although 3 (12.5%) were effectively blind
       (less than 6/60). We conclude that with prompt diagnosis and treatment
       of CMVR vision can be preserved in the majority of cases.
 DE    Adult  AIDS-Related Opportunistic Infections/COMPLICATIONS/*DRUG
       THERAPY/  EPIDEMIOLOGY  Cytomegalovirus Retinitis/COMPLICATIONS/*DRUG
       THERAPY/  EPIDEMIOLOGY  Female  Follow-Up Studies  Foscarnet/ADVERSE
       EFFECTS/*THERAPEUTIC USE  Ganciclovir/ADVERSE EFFECTS/*THERAPEUTIC USE
       Human  Male  Recurrence  Scotland/EPIDEMIOLOGY  Treatment Outcome
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).